Global Lupus Therapeutic Market - Forecasts and Opportunity Assessment by Technavio

Technavio has published a new report on the global lupus therapeutic market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--According to the latest market study released by Technavio, the global lupus therapeutic market is expected to reach USD 2,670.03 million by 2021, growing at a CAGR of almost 10%.

This research report, titled “Global Lupus Therapeutic Market 2017-2021,” provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up-to-date analysis and forecasts for various market segments and all geographical regions.

The global lupus therapeutics market is expected to benefit from a strong pipeline of various newer therapeutics, including regenerative therapy. Although GlaxoSmithKline’s BENLYSTA is the only drug approved for lupus, the off-label use of various drug therapies as per symptoms is substantiating the market growth. The market is expected to accelerate further due to expected approvals of newer drugs till 2021.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio’s healthcare and life sciences research analysts categorize the global lupus therapeutic market into the following segments by drug class. They are:

  • Anti-inflammatory drugs
  • Corticosteroids
  • Immunosuppressant drugs
  • Antimalarial drugs
  • BLyS-specific inhibitors
  • Biologicals
  • Others

The top three drug class segments for the global lupus therapeutic market are discussed below:

Anti-inflammatory drugs

The anti-inflammatory drugs are widely used for most symptoms of lupus as off-label therapy. These drugs reduce the inflammation responsible for the stiffness and discomfort in the muscle, joints, and other tissues.

According to Abhishek Jain, a lead infectious and rare diseases research analyst from Technavio, “Most of the inflammatory drugs are non-selective in nature. Hence, they block both the enzymes, which affects the functioning of some of the organ systems. This also leads to some side effects. However, the newer selective COX-2 inhibitors such as Celecoxib showed better therapeutics with lesser side effects compared with conventional non-selective COX inhibitors.

Corticosteroids

Corticosteroids are widely used therapeutics in lupus disorders. Corticosteroids have dual effects of anti-inflammatory and immunosuppressant. The anti-inflammatory effects are mediated either by direct binding of receptor complex to responsive elements in the promoter region of genes or by the interaction of complex with transcription factors.

The immunosuppressant effects are due to depletion of T-cells, induction of apoptosis, inhibition of T-cell growth factors, and impaired release of cells from lymphoid tissues. It also affects B-cell functioning and thus delays immunoglobulin production,” says Abhishek.

Immunosuppressant drugs

Immunosuppressant drugs are widely used drugs for lupus disorders. As in lupus disorders, the immune system attacks the body’s own tissue and organs due to various triggering factors such as genetic, environmental, or drug-induced factors. Most immunosuppressant drugs work to suppress and downregulate this attack by interfering with the synthesis of deoxyribonucleic acid (DNA).

The immunosuppressant medications can control severe lupus activity that affects major organs in the body. This is a choice of treatment in the majority of cases owing to safer toxicity profile in severe SLE condition when compared with corticosteroids.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • MedImmune
  • Pfizer

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, cardiovascular devices, and life science research tools. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading-edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

According to the latest market study released by Technavio, the global lupus therapeutic market is expected to reach USD 2,670.03 million by 2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com